AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25151339 — intervention group
Group type: EXPERIMENTAL
Intervention: CuZnSOD as a contributor to attention index of RBANS
Number of subjects: 113
Study 22503488 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (LAI)
Number of subjects: 132
Study 22503488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 19059858 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-component physical activity program
Number of subjects: 544
Study 17617857 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion (MP)
Number of subjects: 415
Study 17617857 — intervention group
Group type: COMPARATOR
Intervention: Cold storage (CS)
Number of subjects: 415
Study 15658903 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagectomy (transthoracic or transhiatal)
Number of subjects: 0
Study 15658903 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended esophagectomy with three-field lymphadenectomy
Number of subjects: 0
Study 15658903 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with or without radiotherapy
Number of subjects: 0
Study 15658903 — intervention group
Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy
Number of subjects: 0
Study 15658903 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage esophagectomy
Number of subjects: 0
Study 12193521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birthweight children (LBW)
Number of subjects: 261
Study 9464712 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (60 g daily containing 40 g isolated soy protein)
Number of subjects: 104
Study 7622257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (1,200 mg daily for 15 days)
Number of subjects: 60
Study 7622257 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (2 g daily for 15 days)
Number of subjects: 60
Study 2388013 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonic technique
Number of subjects: 15
Study 2388013 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced forces technique
Number of subjects: 15
Study 2388013 — intervention group
Group type: COMPARATOR
Intervention: Step-back filing technique
Number of subjects: 15
Study 842367 — intervention group
Group type: EXPERIMENTAL
Intervention: Closing of the eyes (experimental condition)
Number of subjects: 7
Study 842367 — intervention group
Group type: COMPARATOR
Intervention: Reading a book (control condition)
Number of subjects: 7
Study 842367 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded (experimental condition)
Number of subjects: 7
Study 31104873 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of crystalline glucosamine sulfate once daily for 6 months
Number of subjects: 42
Study 31104873 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment protocol
Number of subjects: 42
Study 28600466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study 28600466 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 26193781 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine SR (25-mg starting dose)
Number of subjects: 20
Study 26193781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25-mg starting dose)
Number of subjects: 20
Study 24640582 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy plus oral porcine relaxin (pRLX), 20 ug b.i.d for 12 weeks
Number of subjects: 0
Study 24640582 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 0
Study 20666678 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO combination gel
Number of subjects: 3855
Study 20666678 — intervention group
Group type: COMPARATOR
Intervention: Adapalene
Number of subjects: 3855
Study 20666678 — intervention group
Group type: COMPARATOR
Intervention: BPO
Number of subjects: 3855
Study 20666678 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 3855
Study 18762285 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatable high-fat food words
Number of subjects: 99
Study 18251440 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (high intensity intermittent fin-swim training)
Number of subjects: 20
Study 18251440 — intervention group
Group type: COMPARATOR
Intervention: MICT (moderate intensity continuous training)
Number of subjects: 20
Study 15159322 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC) intervention
Number of subjects: 66
Study 15159322 — intervention group
Group type: COMPARATOR
Intervention: Affected with breast and/or ovarian cancer
Number of subjects: 66
Study 15159322 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of cancer-specific distress
Number of subjects: 66
Study 15159322 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceptions of social support
Number of subjects: 66
Study 11233465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 252
Study 11233465 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 252
Study 9726695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vera/Tran (verapamil SR 180 mg/trandolapril 1 mg)
Number of subjects: 51
Study 9726695 — intervention group
Group type: COMPARATOR
Intervention: Meto/HCTZ (metoprolol 100 mg/hydrochlorothiazide 12.5 mg)
Number of subjects: 51
Study 7989857 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource teachers' perceptions of collaborative roles
Number of subjects: 147
Study 7989857 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraints on resource teachers' collaborative role performance
Number of subjects: 147
Study 2661584 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 14
Study 2661584 — intervention group
Group type: COMPARATOR
Intervention: Carrier solution
Number of subjects: 14
Study 4461976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (total body physical fatigue)
Number of subjects: 75
Study 4461976 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (local physical fatigue)
Number of subjects: 75
Study 4461976 — intervention group
Group type: COMPARATOR
Intervention: Group C (rest)
Number of subjects: 75
Study 29466961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (GKRS)
Number of subjects: 23
Study 29466961 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiation therapy (WBRT)
Number of subjects: 23
Study 27221316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 59
Study 26542501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary application of 4 mL of bioabsorbable cardiac matrix (BCM)
Number of subjects: 0
Study 26542501 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 22978318 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboCarrier® insulin
Number of subjects: 0
Study 22978318 — intervention group
Group type: COMPARATOR
Intervention: NPH-insulin
Number of subjects: 0
Study 20102675 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered Food Frequency Questionnaire (FFQ) administered twice (FFQ1 and FFQ2)
Number of subjects: 158
Study 20102675 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered Food Frequency Questionnaire (FFQ)
Number of subjects: 158
Study 18237622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoption of CONSORT in Nursing Research journal
Number of subjects: 100
Study 18237622 — intervention group
Group type: COMPARATOR
Intervention: Quality of reporting in RCTs across 4 nursing journals
Number of subjects: 100
Study 16752669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol (50 microg)
Number of subjects: 198
Study 16752669 — intervention group
Group type: COMPARATOR
Intervention: Transcervical Foley catheter (size 16F)
Number of subjects: 198
Study 14504162 — intervention group
Group type: COMPARATOR
Intervention: Propofol-pronounced anaesthesia (propofol 100 microg x kg(‐1) min(‐1); remifentanil 0.15 microg x kg(‐1) min(‐1))
Number of subjects: 100
Study 14504162 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-pronounced anaesthesia (propofol 50 microg x kg(‐1) min(‐1); remifentanil 0.45 microg x kg(‐1) min(‐1))
Number of subjects: 100
Study 10096971 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic, absorbable sealant
Number of subjects: 26
Study 10096971 — intervention group
Group type: COMPARATOR
Intervention: Standard closure without sealant
Number of subjects: 26
Study 8947088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 mL x kg(‐1) body weight vodka, 40% alcohol by volume)
Number of subjects: 14
Study 8947088 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (ResCare AutoSet)
Number of subjects: 14
Study 8947088 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with Alcohol
Number of subjects: 14
Study 8947088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (without CPAP)
Number of subjects: 14
Study 8947088 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 14
Study 1912129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 12
Study 1912129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7039644 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia and vagal blockade
Number of subjects: 0
Study 7039644 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30657782 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning course on patient safety (ELPAS)
Number of subjects: 463
Study 30657782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no didactic session on patient safety)
Number of subjects: 463
Study 30509367 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1:250,000
Number of subjects: 11
Study 30509367 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1:500,000
Number of subjects: 11
Study 30509367 — intervention group
Group type: COMPARATOR
Intervention: No adrenaline
Number of subjects: 11
Study 28778218 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched treatment (MT) aimed specifically at hip strengthening
Number of subjects: 24
Study 28778218 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 24
Study 25330452 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-FIB I (exercise designed to reduce glycogen of type I muscle fibers)
Number of subjects: 10
Study 25330452 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-FIB II (exercise designed to reduce glycogen of type II muscle fibers)
Number of subjects: 10
Study 25330452 — intervention group
Group type: COMPARATOR
Intervention: CONT (4-km TT without prior exercise)
Number of subjects: 10
Study 25330452 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-FIB I
Number of subjects: 10
Study 25330452 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-FIB II
Number of subjects: 10
Study 24341531 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI <0.9 (Peripheral Arterial Disease - PAD)
Number of subjects: 3307
Study 24341531 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI ≥1.4 (Arterial Calcification - AC)
Number of subjects: 3307
Study 24341531 — intervention group
Group type: COMPARATOR
Intervention: ABI 0.9-1.4 (Healthy)
Number of subjects: 3307
Study 20687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) measurement
Number of subjects: 1000
Study 20687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator and patient questionnaires
Number of subjects: 1000
Study 20687927 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI values at rest
Number of subjects: 1000
Study 19041041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed arterial spin labeling (PASL)
Number of subjects: 10
Study 19041041 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)(15)O PET
Number of subjects: 10
Study 16639345 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg once daily of maraviroc
Number of subjects: 44
Study 16639345 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg twice daily of maraviroc
Number of subjects: 44
Study 16639345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12665537 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g/day)
Number of subjects: 46
Study 12665537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 46
Study 10953403 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access referrals
Number of subjects: 721
Study 10953403 — intervention group
Group type: COMPARATOR
Intervention: Standard letter referrals
Number of subjects: 721
Study 8858671 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (50 mg/kg/day divided twice daily) for 6 days
Number of subjects: 321
Study 8858671 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (45 mg/kg/day divided into three doses/day) for 10 days
Number of subjects: 321
Study 8389688 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 11
Study 3494548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafast cardiac computed tomography (CT)
Number of subjects: 25
Study 29855294 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment
Number of subjects: 2540
Study 29855294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment
Number of subjects: 2540
Study 29855294 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 2540
Study 26913614 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongest Families Smart Website (SFSW) intervention group
Number of subjects: 464
Study 26913614 — intervention group
Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 464
Study 24581924 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 817
Study 24581924 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary study objective (death, MI, or CVA)
Number of subjects: 817
Study 24581924 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 817
Study 22337679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/d)
Number of subjects: 227
Study 22337679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 19748617 — intervention group
Group type: EXPERIMENTAL
Intervention: New incentive system for pressure ulcer management introduced in 39 institutions.
Number of subjects: 105
Study 19748617 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 non-introduced institutions).
Number of subjects: 105
Study 19748617 — intervention group
Group type: EXPERIMENTAL
Intervention: New incentive system for pressure ulcer management.
Number of subjects: 105
Study 17431604 — intervention group
Group type: COMPARATOR
Intervention: 0 mmole oxalate load
Number of subjects: 12
Study 17431604 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mmole oxalate load
Number of subjects: 12
Study 17431604 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mmole oxalate load
Number of subjects: 12
Study 17431604 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mmole oxalate load
Number of subjects: 12
Study 15756419 — intervention group
Group type: EXPERIMENTAL
Intervention: LEF-1 expression in carcinoma samples
Number of subjects: 360
Study 15756419 — intervention group
Group type: EXPERIMENTAL
Intervention: LEF-1 expression in brain cancer samples
Number of subjects: 360
Study 15756419 — intervention group
Group type: COMPARATOR
Intervention: LEF-1 expression in testicular tumor samples
Number of subjects: 360
Study 15756419 — intervention group
Group type: EXPERIMENTAL
Intervention: LEF-1 expression in lymphocytic leukemias
Number of subjects: 360
Study 15756419 — intervention group
Group type: EXPERIMENTAL
Intervention: LEF-1 expression in acute myeloid leukemia and acute lymphocytic leukemia
Number of subjects: 360
Study 11886736 — intervention group
Group type: EXPERIMENTAL
Intervention: Scooting
Number of subjects: 24
Study 11886736 — intervention group
Group type: COMPARATOR
Intervention: Conventional running
Number of subjects: 24
Study 10448286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/LV plus IFN-alpha-2c (30 micrograms subcutaneously, three times weekly)
Number of subjects: 269
Study 10448286 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV (100 mg/m2 intravenously followed by 5-FU, 500 mg/m2 as a 1-h i.v. infusion, daily for 4 days)
Number of subjects: 269
Study 10448286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/LV plus IFN-alpha-2c
Number of subjects: 269
Study 10448286 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 269
Study 8880671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean and Sober Unit (experimental group)
Number of subjects: 189
Study 8880671 — intervention group
Group type: COMPARATOR
Intervention: Unaffiliated shelters (control group)
Number of subjects: 189
Study 8880671 — intervention group
Group type: COMPARATOR
Intervention: Domiciled men (control group)
Number of subjects: 189
Study 1521303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum sweetened with sorbitol
Number of subjects: 0
Study 1521303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum sweetened with sorbitol/xylitol (3:1)
Number of subjects: 0
Study 6240755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (n = 7)
Number of subjects: 42
Study 6240755 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 32)
Number of subjects: 42
Study 6240755 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCR (n = 2 matched patients)
Number of subjects: 42
Study 31647177 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 33
Study 31647177 — intervention group
Group type: COMPARATOR
Intervention: Control (natural healing)
Number of subjects: 33
Study 29558208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the ALL
Number of subjects: 20
Study 29558208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the Kaplan fibers
Number of subjects: 20
Study 29558208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the ACL
Number of subjects: 20
Study 29558208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectioning of the ALL and Kaplan fibers
Number of subjects: 20
Study 27505684 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064 nm long‐pulse Nd:YAG laser treatment
Number of subjects: 9
Study 27505684 — intervention group
Group type: COMPARATOR
Intervention: Control scar (contralateral scar)
Number of subjects: 9
Study 27505684 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked examination of photographs
Number of subjects: 9
Study 27505684 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects reported by subjects and graders
Number of subjects: 9
Study 25369399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (chewed gum >3 hours at a time)
Number of subjects: 51
Study 25369399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (chewed gum 3 hours/day)
Number of subjects: 51
Study 25369399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (chewed gum <1 hour/day)
Number of subjects: 51
Study 25369399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (chewed gum 1-2 hours/day)
Number of subjects: 51
Study 25369399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (chewed gum 1-3 times/week for at least 1 hour each occurrence)
Number of subjects: 51
Study 25369399 — intervention group
Group type: COMPARATOR
Intervention: Group F (didn't chew gum but had other parafunctional oral habits)
Number of subjects: 51
Study 25369399 — intervention group
Group type: COMPARATOR
Intervention: Group G (didn't have parafunctional oral habits)
Number of subjects: 51
Study 22826271 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of doxorubicin/cyclophosphamide (AC) or Paclitaxel (T)
Number of subjects: 3171
Study 22826271 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of doxorubicin/cyclophosphamide (AC) or Paclitaxel (T)
Number of subjects: 3171
Study 20332605 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg epirubicin instillation within 6 hours after TUR-BT
Number of subjects: 299
Study 20332605 — intervention group
Group type: COMPARATOR
Intervention: Double dose of 100 mg epirubicin instillation (second dose during 12th-18th hours after TUR-BT)
Number of subjects: 299
Study 17599428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment arm of the ACCORD trial
Number of subjects: 0
Study 16301244 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 43
Study 16301244 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia (BAL)
Number of subjects: 43
Study 11981389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 20
Study 11981389 — intervention group
Group type: COMPARATOR
Intervention: Hearing Aids
Number of subjects: 20
Study 9862290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Number of subjects: 87
Study 9862290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 7631894 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 11
Study 7631894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1735399 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.7 ml of 0.75% bupivacaine
Number of subjects: 17
Study 1735399 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 17
Study 6367832 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-assisted relaxation training
Number of subjects: 24
Study 6367832 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 31104357 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinjections of human neural stem cells (hNSCs) into the spinal cord
Number of subjects: 18
Study 29972759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 707
Study 29972759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study 25673181 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 465